Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

A Randomized, 4-Period, Crossover Study to characterize the effects of tolperisone 200 mg and 400 mg (supratherapeutic dose) three times a day (TID) over 3 days of dosing on measures of simulated driving performance, cognitive function and drowsiness and compared to placebo and cyclobenzaprine (single-day, residual effect, multiple-day).

Key facts

Study ID

NCT04407377

Run by

Neurana Pharmaceuticals, Inc.

People needed

39

Starts

2020-06-20

Expected to finish

2021-03-31

Last updated by the study team

2022-02-01

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ambulatory male or female, between 21 and 65 years of age, inclusive, for the entire duration of the study (from Screening through Day 3 of last treatment period).
• Body mass index (BMI) range between 18.5 and 30.0 kg/m2, inclusive.
• Subject must possess a valid driver's license and be an active driver and have driven a minimum of 10,000 miles (about 16,000 km) per year for the previous 3 years.
• Subject must demonstrate simulator sickness questionnaire scores that are not indicative of simulator sickness as defined in the driving simulation operations manual.
• Subject must have a regular sleep pattern, not be engaged in shift-work, and in general, have at least 7 hours of sleep each night.

You may not qualify if…

• History of sleep disorders, including insomnia, sleep apnea, Restless Legs Syndrome (RLS), or narcolepsy, night-shift workers, routine daytime napping or oversleeping on weekends days (off work) or a score higher than 10 on the Epworth Sleepiness Scale (ESS) at Screening.
• A history of difficulty in falling asleep or staying asleep in the previous 3 months that is considered clinically significant by the Investigator.
• Subject has traveled across 2 or more time zones (trans meridian travel) in the last 2 weeks prior to randomization or is expected to travel across 2 or more time zones during the study.
• Subject has any physical condition (e.g., severe vision issues, hand use limitations) that would prevent the subject from performing the cognitive or drowsiness assessments.
• Subject has a presence or history of any medically diagnosed, clinically significant psychiatric disorder, including depression, anxiety, insomnia, schizophrenia, or bipolar disorder.
• Consumes more than 3 cups of coffee per day.
• Female subjects who are pregnant or lactating.
• Any clinically significant medical abnormality, any clinically significant chronic disease, or any clinically significant finding on physical examination.
• Subject with a genotype status of poor-, ultrarapid-, or indeterminate- metabolizers of cytochrome CYP2D6.
• Subject is unable to remain in the research unit for each of the treatment periods.
• Subject has visual or auditory impairment which in the opinion of the Investigator would interfere with study related procedures or study conduct.

Where it is running

• CNS Trial — Long Beach, California, United States
• Hassman Research Institute — Berlin, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.